Journal
NMR IN BIOMEDICINE
Volume 25, Issue 9, Pages 1033-1042Publisher
WILEY-BLACKWELL
DOI: 10.1002/nbm.2766
Keywords
choline phospholipid metabolism; glycerophosphodiester phosphodiesterase domain containing 5; choline kinase; MRS; breast cancer
Funding
- National Institutes of Health (NIH) [R01 CA134695]
Ask authors/readers for more resources
Altered choline phospholipid metabolism is a hallmark of cancer, leading to malignant choline metabolite profiles consisting of low glycerophosphocholine (GPC) and high phosphocholine (PC) in human breast cancers. Glycerophosphocholine phosphodiesterase (GPC-PDE) catalyzes the degradation of GPC to free choline and glycerol-3-phosphate. The gene(s) encoding for the GPC-PDE(s) responsible for GPC degradation in breast cancers have not yet been identified. Here, we demonstrate for the first time that the GPC-PDE encoded by glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) is associated with breast cancer malignancy. Two human breast cancer cell lines (n?=?8 and n?=?10) and primary human breast tumor samples (n?=?19) were studied with combined MRS and quantitative reverse transcription-polymerase chain reaction to investigate several isoforms of GDPD expression with respect to choline phospholipid metabolite levels. Of the five GDPDs tested, GDPD5 was found to be significantly overexpressed in highly malignant estrogen receptor negative (ER) compared with weakly malignant estrogen receptor positive (ER+) human breast cancer cells (p?=?0.027) and breast tumors from patients (p?=?0.015). GDPD5 showed significantly positive correlations with PC (p?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available